Alamar Biosciences (NASDAQ:ALMR) Major Shareholder Corporate Gp Vi Ltd. Qiming Sells 111,313 Shares of Stock

Alamar Biosciences, Inc. (NASDAQ:ALMR) major shareholder Corporate Gp Vi Ltd. Qiming sold 111,313 shares of Alamar Biosciences stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $29.89, for a total transaction of $3,327,145.57. Following the completion of the transaction, the insider directly owned 158,967 shares in the company, valued at approximately $4,751,523.63. The trade was a 41.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):

• On Monday, November 2nd, Corporate Gp Vi Ltd. Qiming sold 43,930 shares of Alamar Biosciences stock. The stock was sold at an average price of $29.84, for a total transaction of $1,310,871.20.
• On Friday, October 30th, Corporate Gp Vi Ltd. Qiming sold 143,706 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.38, for a total transaction of $4,365,788.28.
• On Wednesday, October 28th, Corporate Gp Vi Ltd. Qiming sold 100,837 shares of Alamar Biosciences stock. The shares were sold at an average price of $32.77, for a total transaction of $3,304,428.49.
• On Tuesday, October 27th, Corporate Gp Vi Ltd. Qiming sold 84,894 shares of Alamar Biosciences stock. The shares were sold at an average price of $31.39, for a total transaction of $2,664,822.66.
• On Monday, October 26th, Corporate Gp Vi Ltd. Qiming sold 132,524 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.52, for a total transaction of $4,044,632.48.
• On Friday, October 23rd, Corporate Gp Vi Ltd. Qiming sold 147,934 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.59, for a total value of $4,525,301.06.
• On Thursday, October 22nd, Corporate Gp Vi Ltd. Qiming sold 133,811 shares of Alamar Biosciences stock. The stock was sold at an average price of $29.33, for a total value of $3,924,676.63.
• On Wednesday, October 21st, Corporate Gp Vi Ltd. Qiming sold 208,815 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.31, for a total value of $6,329,182.65.
• On Tuesday, October 20th, Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.89, for a total value of $3,960,491.56.
• On Monday, October 19th, Corporate Gp Vi Ltd. Qiming sold 75,508 shares of Alamar Biosciences stock. The stock was sold at an average price of $26.34, for a total value of $1,988,880.72.

Alamar Biosciences Price Performance

Shares of ALMR stock opened at $26.91 on Friday. Alamar Biosciences, Inc. has a 1-year low of $18.84 and a 1-year high of $39.61. The stock’s fifty day simple moving average is $30.24. The company has a current ratio of 11.85, a quick ratio of 10.23 and a debt-to-equity ratio of 0.03. The stock has a market cap of $1.87 billion and a P/E ratio of -13.73.

Alamar Biosciences (NASDAQ:ALMR) last announced its earnings results on Wednesday, November 4th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.03. The business had revenue of $33.55 million for the quarter. As a group, equities research analysts anticipate that Alamar Biosciences, Inc. will post -1.22 earnings per share for the current year.

Alamar Biosciences News Summary

Here are the key news stories impacting Alamar Biosciences this week:

• Positive Sentiment: Alamar reported third-quarter revenue of $33.55 million, up 68%, and a loss of $0.19 per share—narrower than analysts’ expected $0.22 loss. It also raised its 2026 revenue outlook to $121 million–$123 million, supporting its growth outlook. Q3 revenue and guidance
• Positive Sentiment: Alamar and GSK are collaborating on a large-scale proteomics study using Alamar’s platform. The research could increase the platform’s visibility, though no financial terms were disclosed. Alamar and GSK study
• Positive Sentiment: Analysts raised their price targets: TD Cowen lifted its target to $36 and maintained a Buy rating, while BofA Securities raised its target to $35 from $31. These moves indicate improved analyst expectations, though targets are not guarantees. TD Cowen price target BofA Securities price target
• Neutral Sentiment: The company plans to participate in upcoming investor conferences; the announcement did not include new financial guidance or other material business updates. Investor conferences announcement
• Negative Sentiment: Major shareholder Corporate Gp Vi Ltd. Qiming sold 111,313 shares on Nov. 3, after selling 43,930 shares on Nov. 2. The repeated sales—and the reduction in its reported ownership—could add supply and pressure sentiment; the filings do not give a reason for the sales. SEC filing on shareholder sale

Hedge Funds Weigh In On Alamar Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sumitomo Mitsui Trust Group Inc. grew its stake in Alamar Biosciences by 18.5% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 66,913 shares of the company’s stock valued at $2,280,000 after purchasing an additional 10,461 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Alamar Biosciences in the third quarter valued at about $196,000. State Street Corp purchased a new position in shares of Alamar Biosciences in the second quarter worth about $3,930,000. Squarepoint Ops LLC purchased a new position in shares of Alamar Biosciences in the second quarter worth about $283,000. Finally, Braidwell LP purchased a new position in shares of Alamar Biosciences in the second quarter worth about $29,365,000.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on ALMR shares. TD Cowen upped their price objective on shares of Alamar Biosciences from $34.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday. JPMorgan Chase & Co. lifted their target price on shares of Alamar Biosciences from $32.00 to $35.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 11th. Stifel Nicolaus lifted their target price on shares of Alamar Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Finally, Weiss Ratings downgraded shares of Alamar Biosciences from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, October 23rd. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Alamar Biosciences currently has a consensus rating of “Hold” and a consensus target price of $33.00.

About Alamar Biosciences

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.